The complexity of integrins in cancer and new scopes for therapeutic targeting
| dc.contributor.author | Hellyeh Hamidi | |
| dc.contributor.author | Mika Pietilä | |
| dc.contributor.author | Johanna Ivaska | |
| dc.contributor.organization | fi=Turun biotiedekeskus|en=Turku Bioscience Centre| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.18586209670 | |
| dc.contributor.organization-code | 2609201 | |
| dc.converis.publication-id | 17203398 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/17203398 | |
| dc.date.accessioned | 2022-02-25T16:09:02Z | |
| dc.date.available | 2022-02-25T16:09:02Z | |
| dc.description.abstract | <p>Cancer is a complex disease and progresses within a dynamically evolving extracellular matrix that controls virtually every aspect of the tumour and tumour-associated cells. Interactions with the extracellular microenvironment are predominately mediated by a family of cell-surface transmembrane receptors called integrins. Integrin–matrix engagement leads to the formation of adhesion plaques, consisting of signalling and adaptor proteins, at the plasma membrane that link the extracellular matrix to the regulation of the cell cytoskeleton. In this review, we will highlight exciting data that identify new roles for integrins and integrin-dependent signalling in cancer away from the plasma membrane, discuss the implications of integrin-dependent regulation of Met and ErbB2 growth factor receptors and highlight the role of specific integrins in different stages of cancer development including maintenance of cancer stem cells.</p> | |
| dc.format.pagerange | 1017 | |
| dc.format.pagerange | 1023 | |
| dc.identifier.jour-issn | 0007-0920 | |
| dc.identifier.olddbid | 170224 | |
| dc.identifier.oldhandle | 10024/153334 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/29312 | |
| dc.identifier.url | http://www.nature.com/bjc/journal/v115/n9/full/bjc2016312a.html | |
| dc.identifier.urn | URN:NBN:fi-fe2021042715633 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Hamidi, Hellyeh | |
| dc.okm.affiliatedauthor | Pietilä, Mika | |
| dc.okm.affiliatedauthor | Ivaska, Johanna | |
| dc.okm.discipline | 1182 Biochemistry, cell and molecular biology | en_GB |
| dc.okm.discipline | 1182 Biokemia, solu- ja molekyylibiologia | fi_FI |
| dc.okm.internationalcopublication | not an international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | A2 Scientific Article | |
| dc.publisher.country | United Kingdom | en_GB |
| dc.publisher.country | Britannia | fi_FI |
| dc.publisher.country-code | GB | |
| dc.relation.doi | 10.1038/bjc.2016.312 | |
| dc.relation.ispartofjournal | British Journal of Cancer | |
| dc.relation.issue | 9 | |
| dc.relation.volume | 115 | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/153334 | |
| dc.title | The complexity of integrins in cancer and new scopes for therapeutic targeting | |
| dc.year.issued | 2016 |
Tiedostot
1 - 1 / 1
Ladataan...
- Name:
- bjc2016312a.pdf
- Size:
- 643.91 KB
- Format:
- Adobe Portable Document Format
- Description:
- Creative Commons Attribution-NonCommercial-Share-Alike 3.0 licence, original article dx.doi.org/10.1038/bjc.2016.312